Renaissance Capital logo

Legend Biotech Priced, Nasdaq: LEGN

Clinical stage CAR-T immuno-oncology biotech being spun out of GenScript.

Industry: Health Care

Latest Trade: $55.84 0.00 (0.0%)

First Day Return: +60.9%

Return from IPO: +142.8%

Industry: Health Care

We are a global, clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 650 employees in the United States, China and Europe, our differentiated technology, global development and manufacturing strategy and expertise provide us with the ability to generate, test and manufacture next-generation cell therapies targeting indications with high unmet needs. Our lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy we are jointly developing with our strategic partner, Janssen Biotech, Inc., or Janssen, for the treatment of multiple myeloma, or MM. We are developing LCAR-B38M/JNJ-4528 as a potentially improved therapy for MM. LCAR-B38M refers to the product candidate being studied in China, and JNJ-68284528, or JNJ-4528, refers to the product candidate being studied in the rest of the world. Our clinical results achieved to date demonstrate that LCAR-B38M/JNJ-4528 has the potential to deliver deep and durable anti-tumor responses in relapsed and refractory multiple myeloma, or RRMM, patients with a manageable safety profile.
more less
IPO News for Legend Biotech
more
IPO Data
IPO File Date 05/13/2020
Offer Price $23.00
Price Range $18.00 - $20.00
Offer Shares (mm) 18.4
Deal Size ($mm) $424
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 06/05/2020
Offer Price $23.00
Price Range $18.00 - $20.00
Offer Shares (mm) 18.4
Deal Size ($mm) $424
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Somerset, NJ
Founded 2014
Employees 645
Website www.legendbiotech.com